Jesus Martinez, MD
Ophthalmology · Rockville, MDNPI 1902933286
Payments from drug & device makers
Across 222 payments — averaging $36.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$3K
- AbbVie$1K
- Alcon$717
- Rxsight Inc$425
- NEW World Medical,inc.$322
- Sun Pharmaceutical Industries Inc.$279
- plus $2K from 25 others
What the payments were for
- Consulting fees$3,15039%
- Speaking & faculty fees$260%
- Food & beverage$4,71159%
- Education$1362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 8 | $3,150 |
| AbbVie(2 entities) | 75 | $1,225 |
| Alcon | 23 | $717 |
| Rxsight Inc | 7 | $425 |
| NEW World Medical,inc. | 2 | $322 |
| Sun Pharmaceutical Industries Inc. | 10 | $279 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $249 |
| Kala Pharmaceuticals, Inc. | 23 | $171 |
| Mallinckrodt Hospital Products Inc. | 4 | $164 |
| Mallinckrodt Enterprises LLC | 6 | $143 |
| Biotissue Holdings Inc. | 7 | $134 |
| Tearlab Corp | 1 | $121 |
| Glaukos Corporation | 4 | $117 |
| Dompe US, Inc. | 5 | $114 |
| Sight Sciences, Inc. | 4 | $87 |
| Bausch & Lomb Americas Inc. | 3 | $74 |
| Novartis | 5 | $73 |
| Aerie Pharmaceuticals, Inc. | 4 | $70 |
| Harrow Eye, LLC | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $46 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $42 |
| Ocular Therapeutix, Inc. | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $26 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Ivantis, Inc | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Thea Pharma Inc. | 1 | $23 |
| Amgen | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $20 |
| Alcon Research LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,022 in reported general payments places this provider in the 80th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 194 | $321,187 |
| LumiganBimatoprost | 119 | $66,702 |
| XiidraLifitegrast | 49 | $60,412 |
| CombiganBrimonidine Tartrate/Timolol | 76 | $42,416 |
| Cyclosporine | 60 | $33,185 |
| Alphagan PBrimonidine Tartrate | 42 | $24,418 |
| CequaCyclosporine | 18 | $19,135 |
| RhopressaNetarsudil Mesylate | 27 | $14,514 |
| Prednisolone Acetate | 237 | $13,238 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $12,553 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $10,193 |
| Latanoprost | 673 | $9,125 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $8,591 |
| Brinzolamide | 32 | $7,878 |
| Brimonidine Tartrate | 71 | $6,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,225 | $454,723431 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $74 | $65,63263 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $70 | $27,06641 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $279 | $19,13518 claims |
| AlconSimbrinza | $717 | $10,19320 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $46 | $3,39814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Rockville
- Reena GargRockville$200K
- Allen HuHagerstown$47.9M
- David WarrowHagerstown$10M
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- John ThompsonBaltimore$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.